logo
Mum with brain tumour backs research funding calls

Mum with brain tumour backs research funding calls

Yahoo24-03-2025

Georgie Maynard has suffered from regular migraines all her adult life, but one Saturday lunchtime in May 2023 she knew something wasn't right.
"I went out to the garden to get some fresh air and I thought 'no, this light is doing my head in' so I walked inside, sat on the sofa and then it just went bang!
"It was excruciating... I actually thought that was it, I was dying at that moment."
The mother of five from Oxfordshire had suffered a sudden seizure.
Her children called an ambulance and paramedics arrived within minutes.
The 46-year-old was taken to hospital and given a CT scan then sent home.
The following week an MRI scan revealed she had a grade four glioblastoma (GBM) - an aggressive brain tumour.
"It's the worst type of brain tumour," she said.
"One in four live past a year, five per cent last five years.
"It's quite shocking. At that point you've got no belief that that's coming at your door because it's completely out the blue."
Mrs Maynard underwent an awake craniotomy as well as radiotherapy and chemotherapy.
Her latest scan showed the tumour was stable, but she is aware that the average life expectancy following diagnosis is 12 to 15 months.
According to Cancer Research UK, glioblastomas are the most common type of cancerous brain tumour in adults and remain the biggest cancer killer of children and adults under the age of 40.
However, just one per cent of the national spend on cancer research is allocated to the disease.
'They call me a cancer super-survivor'
Man's brain tumour shrinks by half in therapy trial
Extra cancer funding in Tessa Jowell tribute
Mrs Maynard is keen to raise awareness of the condition and do all she can to ensure funding for research is made a priority.
Together with her brother, Charlie Maynard - the Liberal Democrat MP for Witney - Mrs Maynard visited the Centre for Medicines Discovery at Oxford University.
A team led by Prof Daniel Ebner is working on a five-year study to identify existing cancer drugs that might be able to shrink brain tumours.
Out of 10,000 drug combinations, only half a dozen have real potential.
While clinical trials would still be required, because they have already been approved by regulators, Prof Ebner said they could be given to patients within the next five years.
"I'm optimistic for glioblastoma research. Some of the best scientists I've ever worked with are making fantastic breakthroughs," Prof Ebner said.
He added: "Where we would definitely need additional help is with funding to carry a lot of the pre-clinical work we've done to date through to clinical trials. That's the major stumbling block at the moment."
In 2018, the government pledged to invest £40m in research into brain tumours and improve access to clinical trials, following the death of Dame Tessa Jowell.
Nearly seven years later, only about £15m of that £40m has been spent, according to the Brain Tumour Charity.
Mr Maynard said he wanted to know why the remaining money has not been invested.
He said: "There's tonnes of really good research that's crying out for money. It's not doing any good sitting in a bank and I really want some answers.
"Does it exist... and then what are we going to do to spend it and start saving some lives?"
A spokesperson for the Brain Tumour Charity said: "A sustainable and strategic approach to government funding for research into brain tumours is long overdue in order to make progress.
"This should include a broad range of research projects from early-stage understanding - like Prof Ebner's - to late-stage trials.
"At The Brain Tumour Charity we are proud to fund a comprehensive and robust research programme and can only do so thanks to supporters like Georgie."
A Department of Health and Social Care spokesperson said: "We will build on Tessa Jowell's powerful legacy to improve both research and care for brain cancer patients across the UK.
"We spend more than £1.6bn annually on health research and have recently launched two new calls for studies unlocking the next generation of treatments for brain cancer."
You can follow BBC Oxfordshire on Facebook, X, or Instagram.
'My melanoma returned and spread to my brain'
BBC's Glenn Campbell: I want to show what it's like living with a brain tumour
Man with terminal brain tumour welcomes new trial
Mum with terminal cancer's new treatment hope
The Brain Tumour Charity
Cancer Research UK
Nuffield Department of Medicine, University of Oxford

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ClearPoint Neuro, Inc. (CLPT): A Bull Case Theory
ClearPoint Neuro, Inc. (CLPT): A Bull Case Theory

Yahoo

time10 hours ago

  • Yahoo

ClearPoint Neuro, Inc. (CLPT): A Bull Case Theory

We came across a bullish thesis on ClearPoint Neuro, Inc. (CLPT) on M.V. Cunha's Substack. In this article, we will summarize the bulls' thesis on CLPT. ClearPoint Neuro, Inc. (CLPT)'s share was trading at $13.93 as of 6th June. A medical doctor surrounded by advanced technology in the operating room. ClearPoint Neuro is transforming from a surgical tools provider into a critical platform company enabling the next generation of neurological treatments. In the first quarter of 2025, revenue grew 31 percent year-over-year to 8.5 million dollars, led by the rapid adoption of its SmartFrame operating room system, which increased 70 percent and allows hospitals to use ClearPoint technology in standard surgical settings. This expansion seeds a larger installed base and drives high-margin recurring revenue from disposable instruments. The biologics and drug delivery segment generated 4.7 million dollars in revenue, growing 9 percent year-over-year, and is supported by more than 60 active partnerships with gene and cell therapy developers. As these therapies move toward commercial use, ClearPoint's role as the enabling delivery infrastructure could become its most profitable revenue stream, with each procedure generating over 20,000 dollars in high-margin recurring revenue. Meanwhile, the company is intentionally moving away from capital equipment sales, which declined 63 percent, in favor of a subscription-based model that provides predictable recurring revenue. Operating cash burn fell 35 percent in 2024, with expenses rising 29 percent in the latest quarter due to targeted investments in preclinical services, therapy support, and device innovation. ClearPoint closed the quarter with 12.4 million dollars in cash and access to up to 105 million dollars in financing, providing sufficient capital to reach financial breakeven without near-term equity dilution. While risks around execution, partner dependency, and regulatory pacing remain, ClearPoint's embedded position across neurological therapy development offers investors a unique opportunity to benefit from a long-term transformation into the backbone of next-generation brain treatments. Previously, we highlighted a on ClearPoint Neuro from northeasternsvf in January 2025, which emphasized its unique position as the only FDA-cleared, MRI-guided neurosurgical platform enabling precise delivery of CNS gene and cell therapies. That thesis focused on the company's expanding biopharma partnerships, operating room penetration through SmartFrame OR, and its path to profitability via high-margin disposables. ClearPoint Neuro, Inc. (CLPT) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 21 hedge fund portfolios held CLPT at the end of the first quarter which was 13 in the previous quarter. While we acknowledge the risk and potential of CLPT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than CLPT but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.

Caitlin Clark injury update: When will Fever star return? 'We're gonna play the long game'
Caitlin Clark injury update: When will Fever star return? 'We're gonna play the long game'

Indianapolis Star

time10 hours ago

  • Indianapolis Star

Caitlin Clark injury update: When will Fever star return? 'We're gonna play the long game'

INDIANAPOLIS – Caitlin Clark will not play in Tuesday's game at Atlanta, Fever coach Stephanie White said on Monday. Clark's status for the game, which come just over two weeks after she suffered a quad strain, was previously up in the air. Clark didn't rule out playing in the game in her availability on June 3, but said she would need to be re-evaluated and left it up to the Fever's medical staff to make the final decision. Now, that question has been answered. "Not for tomorrow, no," White said Monday when asked if Clark would be available on Tuesday. Personal touches, secret messages: Behind the scenes of making Caitlin Clark's new Wilson basketballs Clark suffered a quad strain sometime during the Fever's game against the New York Liberty on May 24, though she couldn't pinpoint the specific play it happened. She reported some pain after the game and got an MRI, which showed a strain in her left quad. 'Obviously, adrenaline covers up a lot of stuff when you're in the heat of battle,' Clark said during her media availability on June 3. 'And after the game, I had some pain, and then we got an MRI, and that kind of gave me the result that I didn't want to see. But, you know, those types of things don't lie.' Clark's original timeline was that she would be out for two weeks before she would be re-evaluated, setting her re-evaluation date at June 8. She was evaluated this weekend and allowed to begin some aspects of practice again, White said, but not necessarily cleared for basketball activities at the highest level. "I don't know if cleared is the right word, I mean, she's ready to start ramping back up," White said. "But it's completely different when you're just doing 1-on-1 workouts, and when you're out there in 5-on-5, getting up and down the floor, moving laterally. So she's been allowed to do some practicing, not everything. And we're gonna be smart, and we're gonna be cautious, and we're gonna play the long game." Clark participated in the portion of practice open to media Monday afternoon, which were shooting drills from midrange and 3-point range. They went around the arc as a team, making shots from each corner, each wing and the top of the key. Clark didn't seem limited in that portion of practice, running for rebounds and shooting as normal. But shooting drills are much different than actual practice — both in the amount of contact and the intricacies of it. "It's one thing to do some shooting drills," White said. "It's another thing to get out there on the floor, get back into movement patterns, rhythm, timing, and so that's what part of, you know, picking and choosing things that they can be in in practice, so that we can see their progression." White did not provide a specific timeline for Clark's return to the court. The Fever play at Atlanta on Tuesday, then return to Indianapolis and a have a few days off before playing the New York Liberty on Saturday. No, the Fever star will miss her fifth straight game as she recovers from a quad injury. Coach Stephanie White confirmed Monday that Clark would not play on Tuesday.

Sacroiliac MRI Lesions Set Apart axSpA and Other Back Pain
Sacroiliac MRI Lesions Set Apart axSpA and Other Back Pain

Medscape

time16 hours ago

  • Medscape

Sacroiliac MRI Lesions Set Apart axSpA and Other Back Pain

The analysis of structural lesions in sacroiliac joints using MRI showed distinct patterns of structural changes across multiple groups, with patients with axial spondyloarthritis (axSpA) showing higher rates of erosions and fatty lesions than other groups without axSpA. Inflammatory and structural lesions occurred simultaneously in those with axSpA. METHODOLOGY: Researchers assessed differences in the structural lesions appearing on sacroiliac joint MRIs in 172 participants (mean age, 30.1-34.3 years) from two projects comparing patients with axSpA with those without. They included patients with axSpA (n = 47) and those without axSpA comprising patients with chronic back pain (n = 47), women with postpartum back pain (n = 7), runners (n = 24), and healthy individuals (n = 47). Two trained, calibrated readers independently inspected the sacroiliac joint MRIs for erosions, fatty lesions, sclerosis, and ankylosis. A scoring system similar to that of the Spondyloarthritis Research Consortium of Canada scoring method was used for the assessment. Several structural lesion cutoffs were identified and tested as suggested by two working groups, with specific definitions for three or more erosions, three or more fatty lesions, and five or more erosions and/or fatty lesions. The frequency of patients meeting the cutoffs was assessed within different subgroups. TAKEAWAY: Structural lesions were identified in 79% of patients with axSpA and 13% of those without axSpA, with erosions (75% vs 9%) and fatty lesions (40% vs 4%) showing the most marked differences and sclerosis (13% vs 3%) and ankylosis (15% vs 2%) showing smaller group differences. Erosions were also prevalent in women with postpartum back pain (57%), and fatty lesions were the most prevalent in healthy individuals (6%). Significant differences were noted across groups for fatty lesions ( P < .001), erosions ( P < .001), and ankylosis ( P = .016); however, sclerosis showed no significant variation. The proposed cutoff definitions performed well in differentiating axSpA from non-axSpA. < .001), erosions ( < .001), and ankylosis ( = .016); however, sclerosis showed no significant variation. The proposed cutoff definitions performed well in differentiating axSpA from non-axSpA. In the axSpA group, an overlap of 72%-79% was observed between structural lesions and inflammation, while non-axSpA subgroups showed a significantly lower rate of overlap. However, 4%-29% of patients in the non-SpA subgroup compared with only 6% in the axSpA group had structural lesions without inflammation. IN PRACTICE: "We are convinced that if structural lesions ought to be part of axSpA classification criteria, the implementation of cut-offs for these lesions should be considered. Nevertheless, for a comprehensive understanding of the possible added value of structural lesions, it is crucial to look at the prevalence of structural lesions in the absence of inflammation," the authors wrote. SOURCE: This study was led by Zohra Kerami, Amsterdam UMC Locatie AMC, Amsterdam, the Netherlands. It was published online on May 28, 2025, in RMD Open . LIMITATIONS: The sample sizes were notably small for some subgroups. Additionally, comprehensive clinical and demographic information was lacking for healthy individuals, women with postpartum back pain, and runners. Data on previous pregnancies and the interval between MRI and delivery were not collected systematically, which limited the analysis of pregnancy-related effects. DISCLOSURES: This study did not receive any specific funding. Few authors reported receiving consultancy fees, research support, and/or speaking fees and honoraria for lectures or participation in advisory boards from various pharmaceutical companies. One author reported being an associate editor and another reported being an owner of Joint Imaging BV.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store